ライフサイエンスコーパス: Gd-DTPA

1 Gd-DTPA contrast-enhanced (CE) MRI identifies patterns o

2 Gd-DTPA was administered, and the hearts were excised an

3 Gd-DTPA-enhanced infarcts showed high (18)FDG uptake on

4 Gd-DTPA-enhanced MR images acquired 30 minutes after con

5 acid-bismethylamide (Gd-DTPA-BMA) (n = 24), (Gd-DTPA)30-albumin (n = 24) or saline (control group, n

6 e, and the T1-W imaging was repeated after a Gd-DTPA-enhanced 3D magnetic resonance angiogram.

7 inium diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent for dynamic contrast-enhanc

8 inium-diethylene-triamino-penta-acetic acid (Gd-DTPA) infused in the subconjunctival or intrascleral

9 inium diethylene triamine penta-acetic acid (Gd-DTPA) using an inversion-recovery gradient-echo pulse

10 olinium-diethylenetriaminepenta-acetic acid (Gd-DTPA), magnetization transfer (MT) contrast imaging a

11 dolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) pulse sequences were obtained to evaluate synov

12 dolinium diethylenetriaminepentaacetic acid (Gd-DTPA) uptake index was analyzed with respect to the t

13 ed to Gd-diethylenetriaminepentaacetic acid (Gd-DTPA).

14 dolinium diethylenetriaminepentaacetic acid (Gd-DTPA).

15 e in r(1) relaxivity over gadopentetic acid (Gd-DTPA) and have better X-ray absorption ability than r

16 -ESMA) were compared with gadopentetic acid (Gd-DTPA) for infarct size determination, contrast-to-noi

17 olinium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclodode

18 olinium diethylenetriamine pentaacetic acid (Gd-DTPA) enhanced MRI was performed at baseline, 3 hours

19 olinium-diethylenetriamine pentaacetic acid (Gd-DTPA) injection, and the enhancement occurs in region

20 olinium diethylenetriamine pentaacetic acid (Gd-DTPA).

21 ithin the cap, the percent enhancement after Gd-DTPA on T1-W imaging was 91+/-63%.

22 Immediately after Gd-DTPA administration, a high-signal-intensity rim was

23 blood-retinal barrier (BRB) integrity after Gd-DTPA injection intravenously and retinal DeltaPo2 dur

24 were acquired every 6 min until 30 min after Gd-DTPA.

25 e obtained continuously for 40 minutes after Gd-DTPA injection (0.3 mmol/kg).

26 uct (BRB PS') was determined using MRI after Gd-DTPA injection.

27 to-noise ratio (infarct versus septum) after Gd-DTPA injection peaked at 10 minutes and returned to p

28 f the enhanced region varies with time after Gd-DTPA injection and (2) if and when the size of the en

29 MRI requires imaging at specific times after Gd-DTPA injection, and this time varies with the duratio

30 TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

31 bing extravasation of the MRI contrast agent Gd-DTPA was significantly increased in both the sonicate

32 icient (K(trans)) for an MRI contrast agent (Gd-DTPA) was estimated serially at 4-5 time points rangi

33 A gadolinium-containing contrast agent (Gd-DTPA) was infused through microdialysis probes implan

34 to the two gadolinium-based contrast agents (Gd-DTPA and GadoSpin).

35 on, a USPIO in clinical trials, and albumin-(Gd-DTPA)(30) were compared at MR imaging on sequential d

36 an breast cancers underwent dynamic albumin-(Gd-DTPA)(30)-enhanced MR imaging followed by an initial

37 tumor grade with either the soluble albumin-(Gd-DTPA)(30) (r = 0.88; P <.001) or larger particulate U

38 , and K(PS) values derived by using albumin-(Gd-DTPA)(30) in the same tumors.

39 gher diffusivity than sodium diatrizoate and Gd-DTPA.

40 d with various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which served as a

41 ts showed good agreement between Gd-ESMA and Gd-DTPA and were confirmed by ex vivo triphenyltetrazoli

42 rved between delayed enhancement imaging and Gd-DTPA between days 7 and 21 (1.8+/- versus 3.8; P=ns),

43 cosaminoglycan content for sodium iodide and Gd-DTPA only, diffusivity significantly increased for al

44 eases in diffusivities for sodium iodide and Gd-DTPA, with similar (but not significant) trends for s

45 S (cm(3)/min) was measured using DCE-MRI and Gd-DTPA (MW 590 Da) in urethane-anesthetized control rat

46 an +/- standard deviation) with Mn-PyC3A and Gd-DTPA was 476 +/- 77 and 538 +/- 120, respectively (P

47 (Papio anubis; n = 4) by using Mn-PyC3A and Gd-DTPA.

48 lenetriaminepentaacetic acid-bismethylamide (Gd-DTPA-BMA) (n = 24), (Gd-DTPA)30-albumin (n = 24) or s

49 with various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3.

50 pregnant mice after administration of b-BSA-Gd-DTPA and analyzed using a new sub-voxel biophysical s

51 nd recycling associated with the large b-BSA-Gd-DTPA conjugate.

52 ansporters with free biotin suppressed b-BSA-Gd-DTPA uptake.

53 gation of biotinylated contrast agent (b-BSA-Gd-DTPA).

54 n embolic stroke rats, the enhanced areas by Gd-DTPA at 24 h were larger, and the patterns (time, int

55 BBB leakage in the ischemic core measured by Gd-DTPA-enhanced MRI compared with rats treated with sal

56 window for HCC chemotherapy, as monitored by Gd-DTPA-enhanced MRI as a noninvasive, clinically applic

57 ermined for the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found t

58 anded the suprachoroidal layer and delivered Gd-DTPA to the posterior segment.

59 eal implants placed at the equator delivered Gd-DTPA throughout the vitreous cavity and posterior seg

60 s tested by use of intracoronarily delivered Gd-DTPA-labeled fibrinogen thrombi (n=6).

61 ate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics

62 The use of gadopentetate dimeglumine (Gd-DTPA) as a contrast agent showed smaller and less spe

63 Gadopentetate dimeglumine (Gd-DTPA) dynamic magnetic resonance imaging studies show

64 MRI contrast agent gadopentate dimeglumine [Gd-DTPA(2-)]) is used as an index of the molecular statu

65 enhancing lesions detected with single-dose Gd-DTPA by 47% (P < 0.05) and with triple-dose Gd-DTPA b

66 24-72 h apart, with triple- and single-dose Gd-DTPA.

67 le sclerosis, the combination of triple-dose Gd-DTPA and delayed MT imaging more than doubles the sen

68 -DTPA by 47% (P < 0.05) and with triple-dose Gd-DTPA by 27% (P < 0.01).

69 Overall, triple-dose Gd-DTPA resulted in a 75% increase in the number of enha

70 ging with a long delay following triple-dose Gd-DTPA, resulting in the detection of 126% more enhanci

71 verse events possibly related to triple-dose Gd-DTPA.

72 t contrast enhancement with gadolinium-DTPA (Gd-DTPA) could aid in the differentiation of plaque comp

73 -release implant containing gadolinium-DTPA (Gd-DTPA).

74 or the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to be 4.8

75 The degree of extracapsular Gd-DTPA enhancement was assessed in both conditions usin

76 slice surface) correlated well: r = 0.96 for Gd-DTPA-BMA; r = 0.95 for (Gd-DTPA)30-albumin.

77 higher than the transport rate constant for Gd-DTPA movement into the vitreous.

78 The transfer coefficient Ktrans for Gd-DTPA and the drug concentrations showed a good linear

79 so revealed different transport pathways for Gd-DTPA and H(2)(17)O.

80 ell: r = 0.96 for Gd-DTPA-BMA; r = 0.95 for (Gd-DTPA)30-albumin.

81 tional small-molecule contrast agents, e.g., Gd-DTPA (diethylene triamine pentaacetic acid), used cli

82 mmon gadolinium-based contrast agents (e.g., Gd-DTPA, r(1) ~ 3.0 ~ 4.0 mM(-1)s(-1)).

83 Thirty RA patients (97%) had Gd-DTPA-confirmed MCP joint synovitis, and bone edema wa

84 s improved Gd stability compared to bis-5-HT-Gd-DTPA (MPO-Gd) and demonstrates no significant cytotox

85 netriaminepentaacetic acid gadolinium (III) (Gd-DTPA) and demonstrate their usefulness for MRI.

86 netriaminepentaacetato aquo gadolinium(III) (Gd-DTPA) derivative with an octyl substituent, was synth

87 There were marked differences in Gd-DTPA wash-in and washout time constants (wash-in, 0.8

88 Contrast MRI reveals increases in Gd-DTPA uptake in the initially nonenhanced tumor region

89 ncreased the signal intensity from tumors in Gd-DTPA-enhanced MRI.

90 tion, and first-pass perfusion (0.03 mmol/kg Gd-DTPA bolus) at stress and rest (4-6 minutes IV adenos

91 in vivo delivered a mean total of 2.7 microg Gd-DTPA into the vitreous, representing only 0.12% of th

92 cumulation kinetics than the small molecule, Gd-DTPA.

93 egrity was seen using Contrast Enhanced MRI (Gd-DTPA) during the late stage of the disease.

94 Likewise, 11b, a naphthyl Gd-DTPA derivative, was compared to the naphthyl phospho

95 No Gd-DTPA was detected in the posterior segment of the eye

96 Gd-DTPA enhancement and also in areas of no Gd-DTPA enhancement, which were confirmed histologically

97 haracterized with extracellular nonspecific (Gd-DTPA) and necrosis-specific (mesoporphyrin) MR contra

98 ium)/DeltaR1(blood)) after administration of Gd-DTPA was greater in ischemically injured myocardium (

99 both before and after the administration of Gd-DTPA.

100 eye did not deliver a significant amount of Gd-DTPA into the vitreous, and no compound was identifie

101 Suprachoroidal clearance of Gd-DTPA followed first-order kinetics with an average ha

102 Distribution and clearance of Gd-DTPA were measured using DCE-MRI.

103 ere incubated with various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which

104 showed that the elimination rate constant of Gd-DTPA from the subconjunctival space into the episcler

105 The distance for the diffusion of Gd-DTPA away from the probe was calculated to be approxi

106 Furthermore, MRI-based estimates of Gd-DTPA transport across these barriers might be useful

107 has also been applied to assess the fate of Gd-DTPA-BMA-loaded liposomes upon their endosomal intern

108 yed (by 3 to 15 minutes) hyperenhancement of Gd-DTPA contrast-enhanced MRI images occurs frequently i

109 nce microscopy to obtain real-time images of Gd-DTPA diffusion around implanted microdialysis probes.

110 The infusion of Gd-DTPA alters the T1 relaxation time for water protons

111 (28+/-5%) immediately after the injection of Gd-DTPA, although it then gradually receded to match the

112 dic environments show a loss of integrity of Gd-DTPA-BMA analogous to the one observed upon internali

113 sions failed to produce detectable levels of Gd-DTPA in the back of the eye.

114 ose a two-component (slow and fast) model of Gd-DTPA uptake that is designed to quantify the kinetics

115 Steady state concentration profiles of Gd-DTPA around the microdialysis probe were attained wit

116 for 1 hour (T1 of MS-325, 50-100 msec; T1 of Gd-DTPA, 200-400 msec) and strong vascular enhancement o

117 on to create contrast was similar to that of Gd-DTPA alone.

118 ging studies showed a reduction in uptake of Gd-DTPA at the time of minimum pO2 and a recovery at the

119 Assuming the velocity of Gd-DTPA to be equal to the fluid flow velocity, we used

120 ng an increase in the distribution volume of Gd-DTPA-BMA in postischemic myocardium.

121 ned by pulse radiolysis experiments (k((*)OH+Gd-DTPA) = 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-D

122 ) = 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-DTPA-BMA) = 1.9 +/- 0.7 x 10(9) M(-1) s(-1), k((*)OH+

123 On Gd-DTPA-BMA-enhanced images, reperfused myocardial infar

124 signal enhancement was linearly dependent on Gd-DTPA dose (r = 0.91, P < 0.0001).

125 On (Gd-DTPA)30-albumin-enhanced images, reperfused infarctio

126 We injected 0.3 mmol/kg MPO-Gd (or Gd-DTPA as control) and performed magnetic resonance ima

127 us muscle at 9 seconds following Mn-PyC3A or Gd-DTPA injection.

128 Systematic injection of paramagnetic Gd-DTPA did not alter vitreous longitudinal relaxation t

129 and gadolinium diethylenetriamine-pentaacid (Gd-DTPA).

130 ontinuously during step changes in perfusate Gd-DTPA concentration.

131 PGC-Gd-DTPA-F-enhanced MR imaging allows for the in vivo ass

132 ed significantly greater accumulation of PGC-Gd-DTPA-F in the graft area after immune attack initiate

133 17 hours after intravenous injections of PGC-Gd-DTPA-F, followed by histologic examination.

134 5a, a 4,4-diphenylcyclohexyl phosphodiester Gd-DTPA derivative; however, its pharmacokinetic propert

135 Comparing pre- and post-Gd-DTPA images demonstrated minimal choroidal contributi

136 In 124 normal and 20 tumor-bearing rats, Gd-DTPA PGM was administered intravenously in doses of 2

137 Polymer-based implants releasing Gd-DTPA were manufactured and placed in the subconjuncti

138 O binding was present in all regions showing Gd-DTPA enhancement and also in areas of no Gd-DTPA enha

139 At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L . mm

140 /TE 455/9, 7 ms, T2 (TR/TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

141 s and 3.0% +/- 0.3 with alphavbeta3-targeted Gd-DTPA-BOA nanoparticles (P = .03).

142 noise ratio peaked later and was higher than Gd-DTPA (40.8+/-10.4 versus 10.5+/-0.2; P<0.05).

143 nt and much longer blood retention time than Gd-DTPA in mice.

144 Together, these findings establish that Gd-DTPA-based DCE-MRI can noninvasively visualize tumor

145 ted, with three independent techniques, that Gd-DTPA penetrates the plasma membrane, and we observed

146 The Gd-DTPA-enhanced area overestimated infarct size, but th

147 The Gd-DTPA-enhanced region encompasses both viable and nonv

148 The Gd-DTPA-enhanced region on day 2 was larger (32.8+/-0.9%

149 n (0.3+/-3.3%) but reduced thickening in the Gd-DTPA-enhanced rim (8.5+/-5.5%, P<0.05).

150 Bland-Altman analysis revealed that the Gd-DTPA-enhanced region overestimated true infarct size

151 Ex vivo, the Gd-DTPA concentration in the vitreous was 30 times highe

152 y excretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes,

153 eral infusion was successful in transporting Gd-DTPA to the posterior segment from an anterior infusi

154 ese data suggest that one may be able to use Gd-DTPA as a surrogate tracer to estimate DOX delivery t

155 Contrast enhancement MRI using Gd-DTPA provides a method to detect gross and microscopi

156 Dynamic three-dimensional MRI using Gd-DTPA, and possibly other contrast agents, may be usef

157 A 30-fold increase in vitreous Gd-DTPA concentration occurred in the enucleated eyes, s

158 These results in vitro stimulated in vivo Gd-DTPA uptake studies, currently underway, in human gli

159 With Gd-DTPA, T1WI images and permeability related MRI parame

160 ted at unique Asp and Glu positions and with Gd-DTPA-aminohexanoic acid covalently attached at the N-

161 de (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3 on the expression and production of cy

162 -ESMA in the postischemic scar compared with Gd-DTPA.

163 tival or intrascleral space and infused with Gd-DTPA at 1 and 10 muL/min.

164 ot observed in areas that were injected with Gd-DTPA or Gd-dopamine-DOTA (P < .05).

165 e edema was seen in 40 of the 75 joints with Gd-DTPA-proven synovitis (53%), but in only 3 of 49 with

166 When labeled with Gd-DTPA, the PGM-based graft copolymer significantly inc

167 We employed contrast enhancement MRI with Gd-DTPA to detect HT in a rat model of embolic stroke tr

168 Loading of up to 30 wt % Gd-DTPA was achieved, and in vitro release occurred over